Innovating Works
HORIZON-HLTH-2023-IND-06-01
HORIZON-HLTH-2023-IND-06-01: Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU
Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:
Sólo fondo perdido 0 €
European
This call is closed This line is already closed so you can't apply. It closed last day 13-04-2023.
An upcoming call for this aid is expected, the exact start date of call is not yet clear.
Hace más de 25 mes(es) del cierre y aún no tenemos información sobre los proyectos financiados, no parece que se vaya a publicar esta información.
Presentation: Consortium Consortium: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Minimum number of participants.
This aid finances Proyectos:

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:

Identification of the most innovative HTA methods developed by EU-funded projects, which respond to the needs of HTA bodies and are ready to be used in real-life settings. Endorsement by HTA bodies of such innovative methods would allow for advancing HTA methodology and improve evidence-based decision making, and patient access to novel health technologiesDissemination among EU HTA bodies of robust innovative HTA methods and tools developed by EU-funded projects.Harmonisation of HTA expertise across EU though the development of a training programme developed in collaboration with academia. The training should address HTA expertise in general, as wells as expertise in joint HTA to be carried out at EU level in accordance with Regulation (EU) 2021/2282, based on the methodological guid... see more

Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:

Identification of the most innovative HTA methods developed by EU-funded projects, which respond to the needs of HTA bodies and are ready to be used in real-life settings. Endorsement by HTA bodies of such innovative methods would allow for advancing HTA methodology and improve evidence-based decision making, and patient access to novel health technologiesDissemination among EU HTA bodies of robust innovative HTA methods and tools developed by EU-funded projects.Harmonisation of HTA expertise across EU though the development of a training programme developed in collaboration with academia. The training should address HTA expertise in general, as wells as expertise in joint HTA to be carried out at EU level in accordance with Regulation (EU) 2021/2282, based on the methodological guidelines elaborated by the Coordination Group on HTA.Contribution to a successful implementation of the HTA Regulation as well as to building an EU methodological HTA framework fit for purpose and fit for the future. Scope:HTA bodies have the responsibility to assess the added value of new health technologies and advise on its reimbursement and use within a healthcare system. Due to the rapid pace at which technology advance and in order to support decision making in an appropriate manner, HTA experts have to adapt/revise regularly their methodology. Whilst EU-funded projects in the field of HTA have addressed some of the research needs of the HTA bodies (e.g. methods of analysis, use of real-world data, use of patient reported outcomes), translation of their results/recommendations into HTA work remains limited.

Advancing HTA methodology and expertise could benefit from a more systematic dialogue between HTA bodies and academia. Therefore, this action could represent an excellent opportunity for both those generating and those using the evidence to come together and discuss the key HTA methodological issues.

Under the newly adopted Regulation (EU) 2021/2282, the Coordination Group on HTA will have to adopt methodological guidelines for joint HTA work (e.g. joint clinical assessments, joint scientific consultation), to regularly review, and where necessary update them. The project could provide input to issues identified by the Coordination Group as important for future updates/revisions of HTA methodology for joint HTA work.

The topic is divided into two strands of activities, with applicants tackling both in their proposals:

Implementation of innovative HTA methods: EU-funded research projects (e.g. COMED, IMPACT-HTA, HTx, GetReal, EHDEN) developed innovative methods aiming at addressing HTA bodies’ needs. Identifying which of these methods are ready to be used in real-life settings is a first crucial step towards broader uptake and dissemination. Successful implementation of innovative methods in actual HTA practices will contribute to provide a timely response to HTA challenges (e.g. use of real-world data in HTA) also providing a sound scientific resource for updates of methodological guidelines by the Coordination Group on HTA for joint activities as requested by the Regulation (EU) 2021/2282. HTA bodies/agencies participating in such activities will gain expertise in those methods that could be later transferred to other bodies/agencies using the training framework developed in the second strand of work.Advancing HTA expertise across the EU and Associated Countries should be carried out through a training programme tailored to the needs of HTA bodies, which may include twinning activities between HTA bodies/agencies to develop expertise and facilitate knowledge sharing among HTA bodies/agencies in the EU. The training programme is expected to contribute to the harmonisation of HTA practices in the EU that will in turn contribute to a greater consistency of health technology assessments across the EU and Associated Countries. Thus, the training programme should also support the engagement of HTA experts from Member States and EEA countries in carrying out joint HTA work starting January 2025 (i.e. implementation date of the Regulation on HTA), with the aim to produce high-quality and robust joint clinical assessments. The training programme should include all the necessary elements for carrying out robust assessments at national and EU level. Regarding the latter, the training programme should also promote the dissemination of the methodological guidelines to be adopted by the Coordination Group on HTA (based on the methodology developed and fine-tuned by EUnetHTA joint actions and EUnetHTA21 service contract). The proposals should address all of the following activities:

Identification of innovative methods and tools, in particular those developed in EU-funded projects able to address HTA bodies' needs (in different areas: relative effectiveness assessment, cost-effectiveness assessment, etc.)Identifications of barriers to the uptake of these methods (and potential associated tools, e.g. open-source software to run cost-effectiveness analyses)Use cases (based on the needs identified by HTA bodies) to facilitate the endorsement by HTA bodies of innovative methodsDevelopment of an implementation plan including supporting tools and training modules (by researchers, alone or in collaboration with HTA bodies, to be delivered to HTA bodies/agencies)Recommendations for broader dissemination. see less

Temáticas Obligatorias del proyecto: Temática principal: Diagnostic technology Health technology assessment Pharmaceutical development Public health

Consortium characteristics

Scope European : The aid is European, you can apply to this line any company that is part of the European Community.
Tipo y tamaño de organizaciones: The necessary consortium design for the processing of this aid needs:

characteristics of the Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 6 “Maintaining an innovative, sustainable and globally competitive health industry”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to all of the following expected outcomes:
Financial Chapters: The chapters of financing expenses for this line are:
Personnel costs.
Expenses related to personnel working directly on the project are based on actual hours spent, based on company costs, and fixed ratios for certain employees, such as the company's owners.
Subcontracting costs.
Payments to external third parties to perform specific tasks that cannot be performed by the project beneficiaries.
Purchase costs.
They include the acquisition of equipment, amortization, material, licenses or other goods and services necessary for the execution of the project
Other cost categories.
Miscellaneous expenses such as financial costs, audit certificates or participation in events not covered by other categories
Indirect costs.
Overhead costs not directly assignable to the project (such as electricity, rent, or office space), calculated as a fixed 25% of eligible direct costs (excluding subcontracting).
Madurez tecnológica: The processing of this aid requires a minimum technological level in the project of TRL 9:. En esta fase la innovación está en su fase final y es operable en un sin número de condiciones operativas, está probada y disponible para su comercialización y/o producción disponible para la sociedad. Entrega de producto o tecnología para producción en serie y comercialización. + info.
TRL esperado:

Characteristics of financing

Intensidad de la ayuda: Sólo fondo perdido + info
Lost Fund:
0% 25% 50% 75% 100%
For the eligible budget, the intensity of the aid in the form of a lost fund may reach as minimum a 100%.
The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations. The funding rate for CSA projects is 100 % of the eligible costs for all types of organizations.
Guarantees:
does not require guarantees
No existen condiciones financieras para el beneficiario.

Additional information about the call

incentive effect: Esta ayuda no tiene efecto incentivador. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
non -competitive competitive Very competitive
We do not know the total budget of the line
minimis: Esta línea de financiación NO considera una “ayuda de minimis”. You can consult the regulations here.

other advantages

SME seal: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
HORIZON-HLTH-2023-IND-06 Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Sin info.
HORIZON-HLTH-2023-IND-06-02 Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 2 years | next call scheduled for the month of
HORIZON-HLTH-2023-IND-06-01 Supporting the uptake of innovative Health Technology Assessment (HTA) methodology and advancing HTA expertise across EU
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 2 years | next call scheduled for the month of
HORIZON-HLTH-2023-IND-06-04 Modelling and simulation to address regulatory needs in the development of orphan and paediatric medicines
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 2 years | next call scheduled for the month of
HORIZON-HLTH-2023-IND-06-05 Mapping the hurdles for the clinical applications of Advanced Therapy Medicinal Products (ATMPs)
en consorcio: Expected Outcome:This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destinatio...
Cerrada does 2 years | next call scheduled for the month of
HORIZON-HLTH-2023-IND-06-07 Development and harmonisation of methodologies for assessing digital health technologies in Europe
en consorcio: Expected Outcome:This topic aims at addressing digital transition challenges through supporting activities that are enabling or contributing...
Cerrada does 2 years | next call scheduled for the month of